Help Ensure the Safe Use of Secondary Hyperparathyroid Meds
February 2018
The new med etelcalcetide (Parsabiv, PAR-sah-biv) will raise questions about treating hyperparathyroidism in dialysis patients.
Hyperphosphatemia and low vitamin D in renal patients leads to hypocalcemia...which stimulates parathyroid hormone (PTH) release.
This is why the first steps in treating patients with elevated PTH are to control high phosphate and treat vitamin D deficiency.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote